Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Shares Outstanding (Weighted Average) (2016 - 2025)

Lipocine's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $5.4 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 0.67% year-over-year to $5.4 million; the TTM value through Sep 2025 reached $5.4 million, up 0.67%, while the annual FY2024 figure was $5.3 million, 1.31% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $5.4 million in Q3 2025 per LPCN's latest filing, roughly flat from $5.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $88.3 million in Q1 2022 to a low of $5.2 million in Q3 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.7 million, with a median of $5.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 98.03% in 2021, then crashed 94.08% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $86.9 million in 2021, then plummeted by 93.98% to $5.2 million in 2022, then rose by 0.73% to $5.3 million in 2023, then increased by 1.31% to $5.3 million in 2024, then increased by 0.61% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Shares Outstanding (Weighted Average) are $5.4 million (Q3 2025), $5.4 million (Q2 2025), and $5.3 million (Q1 2025).